How to Get Leqvio (Inclisiran) in New Mexico

What Is Leqvio and Why It Matters for New Mexico Patients

Leqvio is a small interfering RNA (siRNA) therapy that silences the gene encoding PCSK9 inside hepatocytes, producing a durable reduction in LDL-C that persists between twice-yearly doses. New Mexico has one of the higher rates of cardiovascular disease mortality in the Mountain West, with the CDC reporting age-adjusted heart disease death rates for New Mexico at approximately 152.7 per 100,000 population as of 2021 [1]. That burden makes access to advanced lipid-lowering therapies medically relevant for a meaningful share of the state's adult population.

Unlike statins or ezetimibe, inclisiran does not require daily self-administration. A clinician or nurse administers the 284 mg subcutaneous injection at the office, which removes adherence variability from the equation. The ORION-10 trial (N=1,561, published in NEJM 2020) demonstrated a 52.3% placebo-adjusted LDL-C reduction at day 510 among patients with ASCVD on maximally tolerated statin therapy [2]. A companion trial, ORION-11 (N=1,617, same publication cohort), showed a 49.9% placebo-adjusted reduction at day 510 in a mixed HeFH and high cardiovascular-risk population [2]. Both reductions were sustained through the full observation period without dose escalation.

The ACC/AHA 2022 guideline on nonstatin therapies states that "PCSK9 inhibitors and inclisiran are reasonable additions to maximally tolerated statin therapy when LDL-C remains above 70 mg/dL in very high-risk ASCVD" [3]. Inclisiran's siRNA mechanism distinguishes it from the monoclonal antibody PCSK9 inhibitors (evolocumab and alirocumab), though the LDL-C effect magnitude is comparable [4].

Who Qualifies for a Leqvio Prescription in New Mexico

FDA labeling restricts inclisiran to two populations: adults with primary hyperlipidemia including HeFH, and adults with established clinical ASCVD. Meeting either criterion is the clinical starting point before any New Mexico provider will write the prescription.

Established ASCVD covers prior myocardial infarction, prior stroke, symptomatic peripheral arterial disease, or coronary revascularization. A patient who has had a stent placed or bypass surgery qualifies. HeFH diagnosis can be confirmed by the Dutch Lipid Clinic Network criteria, Simon Broome criteria, or a confirmed LDLR/APOB/PCSK9/LDLRAP1 pathogenic variant on genetic testing [5].

The FDA label also requires that patients be on maximally tolerated statin therapy, defined as the highest statin dose the patient tolerates without unacceptable adverse effects [6]. A prescriber documenting complete statin intolerance must record that history in the medical record; commercial payers in New Mexico will ask for this documentation during prior authorization. Ezetimibe use is not mandated by the label, but many New Mexico payer prior authorization forms ask whether it has been tried.

A fasting lipid panel with LDL-C above 70 mg/dL (very high-risk ASCVD) or above 100 mg/dL (high-risk categories) while on background therapy is the most common numeric threshold payers apply [3].

Required Lab Work Before Starting Leqvio in New Mexico

A fasting lipid panel is the minimum pre-treatment lab requirement. Most New Mexico cardiologists and telehealth providers order a broader baseline panel.

The standard pre-treatment panel includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• Hepatic function panel (AST, ALT, total bilirubin, albumin)
• Complete metabolic panel
• HbA1c or fasting glucose if metabolic syndrome is suspected

Inclisiran itself does not require ongoing liver-enzyme monitoring per FDA labeling, but the hepatic function panel establishes a baseline given that the drug acts inside hepatocytes [6]. Labs must typically be dated within 90 days of the prescription to satisfy prior authorization. LabCorp, Quest Diagnostics, and Tricore Reference Laboratories all operate collection sites throughout New Mexico, including Albuquerque, Santa Fe, Las Cruces, and Farmington. Many telehealth providers who prescribe inclisiran in New Mexico can electronically order labs to the nearest draw site before the telehealth consultation closes.

The ACC recommends repeating a fasting lipid panel at 4 to 12 weeks after the first inclisiran dose and again at 4 to 12 weeks after the second dose on day 90 to confirm the treatment response and document LDL-C reduction for ongoing payer justification [3].

How to Get a Leqvio Prescription Through Telehealth in New Mexico

New Mexico law permits telehealth prescribing of non-controlled prescription medications, including inclisiran, provided the prescriber holds a valid New Mexico medical license and establishes a patient-provider relationship through a synchronous audio-video encounter or through an asynchronous review of a complete medical history [7]. A telephone-only visit does not satisfy the patient-provider relationship standard for a new prescription under New Mexico Administrative Code 16.10.18.

The practical steps for a telehealth Leqvio prescription in New Mexico are:

1. Complete an intake form documenting ASCVD or HeFH diagnosis, current statin therapy (dose and drug name), any prior statin intolerance, and current LDL-C from a lab dated within 90 days.
2. Attend a synchronous video visit with a licensed New Mexico prescriber (MD, DO, NP, or PA, all are authorized to prescribe inclisiran under NM scope of practice law).
3. Receive the electronic prescription sent to a specialty pharmacy enrolled in Novartis's distribution network.
4. The specialty pharmacy ships the drug cold-chain to a New Mexico clinical site (a physician office, cardiology clinic, or qualified infusion center) for administration. The drug cannot be self-injected at home.
5. Attend the in-person injection appointment at the chosen clinical site.

HealthRX providers licensed in New Mexico complete steps 1 through 3 entirely online. Step 5 requires the patient to identify a local injection site. Cardiologists and internal medicine offices in Albuquerque, Rio Rancho, Santa Fe, Roswell, and Las Cruces have administered inclisiran to telehealth-originated patients. If no existing cardiologist relationship exists, many primary care offices in New Mexico will administer the injection after receiving the specialty pharmacy shipment and reviewing the clinical notes.

Prior Authorization Requirements for Leqvio in New Mexico

Prior authorization (PA) is required by nearly every commercial payer operating in New Mexico, including BlueCross BlueShield of New Mexico, Presbyterian Health Plan, Molina Healthcare (commercial line), and Cigna/Evernorth. New Mexico Medicaid does not currently cover inclisiran on its preferred drug list.

A standard PA submission for inclisiran in New Mexico typically requires:

• Confirmed diagnosis code (ICD-10 Z84.01 for family history of HeFH, or the applicable ASCVD code such as I25.10)
• Most recent fasting LDL-C value and date
• Documentation of maximally tolerated statin therapy (drug name, dose, duration)
• Documentation of statin intolerance, if applicable (dates, symptoms, prior statin trials)
• Evidence of prior ezetimibe trial in most PA forms (some payers accept a documented contraindication)
• Prescriber NPI and New Mexico license number

The ACC/AHA Cholesterol Guideline Implementation Task Force has noted that PA processes for PCSK9-class and siRNA therapies "create meaningful delays averaging 3 to 6 weeks from submission to approval," and that incomplete documentation is the leading cause of initial denial [3]. Submitting all four documentation elements at the time of the initial PA submission reduces the denial rate substantially.

Step therapy requirements vary. BlueCross BlueShield of New Mexico commercial plans have historically required documented trials of both a statin and ezetimibe before approving inclisiran. Presbyterian Health Plan commercial formulary places inclisiran in a specialty tier requiring PA but does not mandate a failed PCSK9 monoclonal antibody trial before approval [8]. Always verify the current formulary at time of prescription because commercial formularies update quarterly.

For patients facing PA denial, Novartis offers a free PA support service through the Leqvio Together program, including appeal letter templates and a dedicated reimbursement hotline [9].

Cost and Patient Assistance Programs in New Mexico

The wholesale acquisition cost of inclisiran is approximately $3,250 per injection, or roughly $6,500 per year after the loading dose period. Without insurance coverage, that cost is prohibitive for most patients.

Novartis's Leqvio Together patient assistance program provides inclisiran at no cost for commercially uninsured patients who meet income eligibility criteria (generally household income at or below 400% of the federal poverty level) [9]. Patients with commercial insurance who meet copay assistance eligibility may pay as little as $0 per injection through the manufacturer's copay card, subject to plan eligibility rules.

The manufacturer's program does not cover Medicare Part D patients due to federal anti-kickback statute limitations. Medicare patients in New Mexico may explore the Low Income Subsidy (Extra Help) program through the Social Security Administration, or appeal to their Part D plan for a medical exception if their LDL-C remains uncontrolled [10].

New Mexico does not have a state pharmaceutical assistance program specifically covering PCSK9-class or siRNA lipid-lowering agents as of 2025. Patients who are denied through both commercial insurance and the manufacturer program may consider clinical trial enrollment. The ORION-8 open-label extension trial demonstrated that the 50% LDL-C reduction was maintained at 3 years with no new safety signals [11], and ongoing trials involving inclisiran are listed at ClinicalTrials.gov.

Compounding and 503A Pharmacies in New Mexico

Inclisiran cannot be compounded by a 503A pharmacy in New Mexico or any other state. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a drug that is essentially a copy of an FDA-approved commercially available product cannot be compounded unless a drug shortage is declared by FDA [12]. Inclisiran (Leqvio) is commercially available and is not on the FDA drug shortage list as of mid-2025.

Beyond the legal prohibition, inclisiran's mechanism relies on a precisely engineered GalNAc-conjugated siRNA structure. The N-acetylgalactosamine conjugate targets asialoglycoprotein receptors on hepatocytes and is essential for the drug's hepatocyte-specific uptake and silencing effect [13]. Replicating that conjugation chemistry outside a pharmaceutical manufacturing facility is not feasible at the 503A compounding scale. Any product marketed as "compounded inclisiran" in New Mexico would lack both legal standing and the biochemical structure required for the drug to work.

Patients encountering websites offering compounded inclisiran should treat that as a red flag for pharmaceutical fraud. The FDA MedWatch program accepts reports of illegally marketed drug products at fda.gov/safety/medwatch [14].

What to Expect on Injection Day in New Mexico

The 284 mg dose is supplied as a 1.5 mL solution in a single-dose prefilled syringe. Administration takes under two minutes at the clinical site. The subcutaneous injection is given in the abdomen, upper arm, or thigh, rotating sites across visits [6].

Common injection-site reactions include mild redness, swelling, or bruising at the injection site. In the ORION-10 and ORION-11 trials, injection-site reactions occurred in 2.6% of inclisiran patients versus 0.9% of placebo patients and were predominantly mild and self-limiting [2]. No anaphylaxis cases were reported across the combined ORION program [2].

Patients do not need to fast before the injection visit. Driving after the injection is permitted. The next scheduled injection is exactly 90 days after the first injection (the day-90 loading dose), and then every 6 months thereafter. Patients who miss an injection by more than 3 months should contact their provider; the FDA label states the drug can be restarted without re-titration if a dose is missed [6].

LDL-C monitoring at 90 days after each injection is the standard of care per ACC guidance [3]. A 40 to 55% LDL-C reduction from baseline is a typical clinical response [2]. If the reduction is <30% at the 90-day recheck, the provider should review statin adherence, dietary changes, and whether a secondary cause of hyperlipidemia (hypothyroidism, nephrotic syndrome) has been missed [5].

Transferring an Existing Leqvio Prescription to New Mexico

Patients relocating to New Mexico with an active inclisiran prescription issued in another state face a straightforward path. Inclisiran is a non-controlled Schedule legend drug, so it is not subject to the interstate controlled substance transfer restrictions that apply to opioids or benzodiazepines. A New Mexico-licensed specialty pharmacy enrolled in the Novartis distribution network can receive a transferred prescription.

The practical complication is that inclisiran is distributed through a limited specialty pharmacy network. The transferring pharmacy must be in the same network, or the originating prescriber must issue a new prescription to a New Mexico-accessible pharmacy. If the original prescriber is no longer in-network or in-state, a new prescription from a New Mexico provider resolves the issue. Prior authorization must be re-initiated with the New Mexico insurer even if PA was active with the prior state's insurer, as PA approvals are payer-specific and non-transferable across state lines.

HealthRX providers can review imported records during a telehealth visit and issue a new New Mexico prescription, typically within one business day of a completed video consultation, allowing patients to resume their injection schedule without a gap.

Who Can Prescribe Leqvio in New Mexico

Any licensed New Mexico prescriber with full prescribing authority can write an inclisiran prescription. That includes:

• Physicians (MD, DO) licensed by the New Mexico Medical Board
• Nurse practitioners (APRN-CNP) with full practice authority under New Mexico Nurse Practice Act (New Mexico does not require physician oversight for NP prescribing)
• Physician assistants (PA-C) with a supervising or collaborating physician agreement on file with the New Mexico Medical Board [15]

New Mexico is a full practice authority state for nurse practitioners, which means an NP can independently evaluate, diagnose, and prescribe inclisiran without a physician co-signature. This makes telehealth access through NP-staffed platforms fully compliant with state law.

Pharmacists in New Mexico do not have collaborative practice authority to independently prescribe inclisiran without an initiating prescriber order. A pharmacist may, however, coordinate the specialty pharmacy logistics and administer the injection in a clinical pharmacy setting under a standing order from a supervising physician, depending on the individual pharmacy's protocols.

Cardiologists and lipidologists are the most common prescribers, but endocrinologists (for FH patients), internists, and family medicine physicians in New Mexico all prescribe inclisiran regularly. The drug does not require specialist-only prescribing, and the ACC has encouraged primary care adoption for appropriate patients [3].